Drug intelligence / Profile preview

cefuroxime + ciprofloxacin

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular, Ophthalmic, Otic

Overview

This is a combination of two antibiotics with different mechanisms of action. Cefuroxime is a second-generation cephalosporin that inhibits bacterial cell wall synthesis. It is effective against many gram-positive and gram-negative bacteria. Ciprofloxacin is a second-generation fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication. This combination may be used for various bacterial infections, though it is not formulated as a single product.

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cefuroxime + ciprofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefuroxime + ciprofloxacin.

Explore the full profile